Cohort study of idiopathic retroperitoneal fibrosis in China
Official title: A Prospective Cohort Study of Idiopathic Retroperitoneal Fibrosis in China
Run by Peking Union Medical College Hospital · NCT04312854 · Data updated 2026-11-12
This study looks at how idiopathic retroperitoneal fibrosis affects patients in China and how they respond to different treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 17, 2020 |
| Main results expected | January 2030 |
| Study ends | January 2030 |
| Registry record updated | March 18, 2020 |
| Trial ID | NCT04312854 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are males and females aged 18-75 diagnosed with definite or possible idiopathic retroperitoneal fibrosis.
✕Probably not a fit
Patients with malignancies, other autoimmune diseases, or secondary forms of retroperitoneal fibrosis will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cohort study aims to investigate the disease course and treatment response of patients with idiopathic retroperitoneal fibrosis (IRPF) across China. Patients diagnosed with definite or possible IRPF will be enrolled, and an online database will be established to collect clinical manifestations, demographic features, laboratory characteristics, immunological tests, imaging, and pathological features. The study will focus on understanding the complex clinical phenotype of IRPF and its association with other autoimmune conditions. The primary endpoint is to document the clinical manifestations of IRPF patients, while secondary endpoints will explore various characteristics and treatment outcomes.
Why it matters
Potential benefit: If successful, this study could enhance understanding of IRPF and improve treatment strategies for affected patients.
How similar studies have gone: While there may be limited studies on IRPF, this cohort approach is novel in the context of a comprehensive registry in China.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Males and females; 18-75 years old with informed consent; Patients diagnosed with definite or possible IRPF. Exclusion Criteria: Secondary forms of IRPF; Pregnant or Females planning to bear a child recently ; Concurrent severe and/or uncontrolled and/or unstable diseases; Patients with malignancy.
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Wen Zhang, MD — Department of Rheumatology,Peking Union Medical College Hospital
- Study coordinator: Yunyun Fei, MD
- Email: feiyunyun2013@hotmail.com
- Phone: 86-10-69158797
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis
This study tests if stopping steroid treatment early can be safe and effective for adults with idiopathic retroperitoneal fibrosis.
-
National registry for idiopathic retroperitoneal fibrosis in China
This study is trying to gather information from patients with idiopathic retroperitoneal fibrosis in China to better understand the condition and its effects on people's health.
-
National Registry for Rare Kidney Diseases
This study is collecting health information from people with rare kidney diseases to help improve treatments and create better care guidelines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.